Document text
Principal Investigator: Heinrich Feldmann
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $208,265
Funding agency: National Institute of Allergy and Infectious Diseases
The global public health burden caused by SARS-CoV-2 and its resulting disease, COVID-19, has driven the rapid development of vaccines and treatment options. However, the continued emergence of novel SARS-CoV-2 variants of concern (VOC), which rapidly and globally replace earlier, previously predominant strains, and the diminished efficacy of current vaccines and certain treatments against infection by these VOC has raised concerns. Therefore, additional vaccine and therapeutic approaches are urgently needed.
DMTs work had three major objectives: (i) Develop animal disease and infection models and study pathogenesis; (ii) repurpose existing drug compounds and evaluate their therapeutic potential in those animal models; (iii) develop vaccines and perform efficacy testing utilizing those animal models.
Animal Models Program
Last year, we reported on the establishment of an intranasal Syrian hamster disease model for SARS-CoV-2 recapitulating mild to moderate human COVID-19. SARS-CoV-2 replication in the respiratory tract peaked within days with animals showing mild respiratory disease followed by complete recovery (Rosenke et al., Emerg Microbes Infect 2020). To avoid infection at one key site of virus replication, we followed up with an intramuscular infection model in Syrian hamsters. The model showed similar disease and replication characteristics, but the ID50 was about 3 log10 higher (Rosenke et al., manuscript in preparation). Using the intranasal hamster model, we demonstrated that prior SARS-CoV-2 infection prevents acute disease and lung pathology in reinfected hamsters but not virus replication despite substantial levels of humoral immunity. These findings denoted the potential for transmission through reinfected asymptomatic individuals (Hansen et al., Cell Reports 2022).
Throughout this year, we have investigated other animal species as disease/infection models such as young pigs, which were not susceptible to SARS-CoV-2 (Haddock et al., Microorganisms 2022). Squirrel monkeys are also not susceptible to SARS-CoV-2 (Okumura et al., in preparation).
We refined the rhesus macaque and established the African green monkey (AGM) model for SARS-CoV-2 infection (Clancy et al., Vet Pathol 2021). Severe COVID-19 has been associated with T cell lymphopenia. Thus, we used the rhesus macaque model and studied SARS-CoV-2 infection following depletion of either CD4+, CD8+, or both T cell subsets prior to infection. The study indicated that while T cells play a role in recovery from acute SARS-CoV-2 infection, their depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severe COVID-19 (Hasenkrug et al., mBio 2021). To better define pathogenicity of different SARS-CoV-2 VOCs we used the rhesus and AGM models. Intranasal infections of AGMs with either a contemporary D614G SARS-CoV-2 variant or the Alpha VOC caused indistinguishable mild respiratory disease. Significantly higher levels of SARS-CoV-2 replication were found in the respiratory tract from Alpha-infected animals suggesting increased pathogenicity (Rosenke et al., Emerg Microbes Infect 2021). Using the rhesus macaque model we have shown that the Omicron VOC possessed reduced pathogenicity and replication compared to the Delta and other previous VOVs (van Doremalen et al., submitted).
Therapeutic Program
Early 2020, we started a therapeutic project focusing on repurposing drugs for use against SARS-CoV-2. We established a drug pipeline starting with literature search selecting potential drug candidates (Jarvis et al., Antivir Ther 2020). Next, we used different cell culture systems to define the in vitro efficacy against SARS-CoV-2 and determined the EC50 values of the drugs (Haddock et al., Am J Trop Med Hyg 2021). Finally, we tested promising candidates in the hamster and rhesus macaque model.
We could show that despite potent in vitro activity, hydroxychloroquine failed to inhibit SARS-CoV-2 in the hamster and rhesus macaque model (Rosenke et al., JCI Insight 2020; Funnell et al., Nat Commun 2020). Several other drugs showed potent in vitro efficacy with favorable EC50 values, but also failed to protect hamsters against SARS-CoV-2 infection unpublished.
We next tested the in vivo efficacy of orally delivered molnupiravir in the hamster model, the lead candidate from in vitro testing. We demonstrated potent inhibitory efficacy of molnupiravir on SARS-CoV-2 replication especially in the lower respiratory tract (Rosenke et al., Nat Commun 2021; Rosenke et al., JCI Insight 2022). This supported the establishment of molnupiravir as a treatment for human COVID cases. Currently, we are testing the in vivo efficacy of molnupiravir against Delta and Omicron in the hamster and rhesus macaque models with the final goal of combination therapy.
Vaccine Program
In collaboration with the University of Washington and HDT Bio, we established a self-amplifying mRNA vaccine platform based on the alphavirus RNA genome technology to express the SARS-CoV-2 spike protein. For vaccine delivery, we utilized a nanostructured lipid carrier developed by HDT Bio. Initially, we demonstrated that the vaccine candidate was potent in elucidating neutralizing antibody and T cell responses in two animal models (Erasmus et al., Sc Transl Med 2020). Next, we showed that SARS-CoV-2 variant-specific replicating RNA vaccines protected hamsters from disease and pathology and reduced viral shedding following challenge with heterologous VOCs (Hawman et al., eLife 2022). Subsequently, we rapidly developed an Omicron-targeting vaccine and found that mice previously immunized with an ancestral-targeting vaccine failed to elevate neutralizing antibody titers against Omicron following Omicron-targeted boosting. Furthermore, we found that our Omicron-targeted vaccine provides superior protection compared to an ancestral variant-targeted vaccine in hamsters challenged with Omicron. Thus, Omicron-targeted vaccines may provide superior protection against Omicron, but pre-existing immunity and timing of boosting may need to be considered for optimum protection (Hawman et al., eLife 2022).
We collaborated with Michael Diamonds group at Washington University on a chimpanzee-adenovirus vectored SARS-CoV-2 vaccine expressing the spike protein. A single intranasal dose of ChAd-SARS-CoV-2-S administered to rhesus macaques induced neutralizing antibodies and T cell responses and limited or prevented infection in the respiratory tracts after SARS-CoV-2 challenge (Hassan et al., Cell Rep Med 2021). The clinical trial of this vaccine is headed by our collaborators at Washington University.
We also evaluated a DNA vaccine against SARS-CoV-2 in the Syrian hamster model. Hamsters were vaccinated with a DNA-plasmid encoding the SARS-CoV-2 spike protein. Hamsters receiving prime-boost-boost vaccinations by the intramuscular route only recovered quicker, had decreased lung viral loads, and increased SARS-CoV-2-specific antibody titers compared to control vaccinated animals, but lung pathology was as severe as in controls. Vaccination by the intramuscular/intranasal combination route showed no efficacy in reducing lung virus titers or pathology. This data demonstrated that dependent on vaccine context, significant antibody responses and decreased viral loads may not be sufficient to prevent lung pathology (Leventhal et al., Microorganisms 2021).
Field Site Program
In February 2020 we established diagnostic testing for the emerging SARS-CoV-2 at our ICER site in Bamako, Mali. At a time, Mali did not report any COVId-19 cases, but the situation changed quickly and the ICER site (Point G) became a key national diagnostic center for COVID testing in Mali. We continued our diagnostic support throughout FY21/22.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Active Follow-up><Acute><Acute Disease><Ad vector><Adenoviral Vector><Adenovirus Vector><African Green Monkey><Alpha Virus><Alphavirus><Animal Disease Models><Animal Diseases><Animal Model><Animal Models and Related Studies><Animals><Antibody Response><Antibody titer measurement><Antiviral Agents><Antiviral Drugs><Antivirals><CD8><CD8B><CD8B1><CD8B1 gene><COVID><COVID testing><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture System><Cells><Chad><Characteristics><Chimp><Chimpanzee><Chlorocebus aethiops><Chlorocebus sabaeus><CoV disease><CoV-2><CoV2><Collaborations><Combined Modality Therapy><Containment><Cricetinae><DNA Vaccines><Data><Development><Diagnostic><Diagnostic tests><Diamond><Disease><Disease model><Disorder><Dose><Drug Compounding><Drug Preparation><Drug usage><Drugs><Dysfunction><Emerging Communicable Diseases><Emerging Infectious Diseases><Family suidae><Fostering><Functional disorder><Genome><Goals><Golden Hamsters><Golden Syrian Hamsters><Green Monkey><Group A Arboviruses><Hamsters><Hamsters Mammals><Human><Humoral Immunities><Hydroxychlorochin><Hydroxychloroquine><Immune response><Immunity><Immunize><Immunological response><In Vitro><Individual><Infection><Infection prevention><International><Intramuscular><LYT3><Lipids><Literature><Lower respiratory tract structure><Lung><Lung Respiratory System><Lymphocytopenia><Lymphopenia><M mulatta><M. mulatta><Macaca mulatta><Mali><Manuscripts><Medication><Mesocricetus auratus><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NIAID><NIH><Naked DNA Vaccines><Nanostructures><National Institute of Allergy and Infectious Disease><National Institutes of Health><Natural Resistance><Non-Polyadenylated RNA><Oral><Oxychlorochin><Oxychloroquine><Pan Genus><Pan Species><Pathogenesis><Pathogenicity><Pathology><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiopathology><Pigs><Play><Preparation><Prevent infection><Proteins><Public Health><Pulmonary Body System><Pulmonary Organ System><Pulmonary Pathology><RNA><RNA Gene Products><RNA vaccine><RNA-based vaccine><Recombinant DNA Vaccines><Recovery><Reporting><Research><Respiratory Disease><Respiratory System><Respiratory System Disease><Respiratory System Disorder><Respiratory Tracts><Respiratory tract structure><Rhesus><Rhesus Macaque><Rhesus Monkey><Ribonucleic Acid><Role><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pathogenesis><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Saimiri><Saimirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Squirrel Monkey><Suidae><Swine><Syrian Hamsters><T cell response><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><Technology><Testing><Therapeutic><Time><Transmission><United States National Institutes of Health><Universities><Vaccinated><Vaccination><Vaccine Clinical Trial><Vaccines><Variant><Variation><Viral><Viral Burden><Viral Diseases><Viral Load><Viral Load result><Viral Shedding><Virus><Virus Diseases><Virus Replication><Virus Shedding><Washington><Work><Wuhan coronavirus><active followup><acute disease/disorder><acute disorder><adeno vector><adenovector><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after severe acute respiratory distress syndrome CoV-2 infection><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody titering><antibody-based immunity><antiviral compound><antiviral medication><antiviral therapeutic><base><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><combination therapy><combined modality treatment><combined treatment><communicable disease transmission><corona virus disease><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease testing><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus testing><deliver vaccines><develop a vaccine><develop vaccines><development of a vaccine><developmental><disease transmission><disorder model><drug candidate><drug repurposing><drug use><drug/agent><efficacy testing><follow up><follow-up><followed up><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following severe acute respiratory distress syndrome CoV-2 infection><followup><hCoV19><host response><immune system response><immunoresponse><in vitro activity><in vitro testing><in vivo evaluation><in vivo testing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infectious disease transmission><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><insight><lead candidate><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lower respiratory tract><lung pathology><mRNA vaccine><mRNA-based vaccine><microorganism><model of animal><model organism><molnupiravir><multi-modal therapy><multi-modal treatment><nCoV2><nano-structures><naturally resistant><neutralizing antibody><novel><pathogenic virus><pathophysiology><plasmid DNA><porcine><post SARS-CoV-2 infection><prevent><preventing><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><programs><pulmonary><repurposing agent><repurposing medication><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><suid><testing for COVID><testing of COVID><thymus derived lymphocyte><transmission process><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine delivery><vaccine development><vaccine for novel coronavirus><vaccine platform><variants of concern><viral infection><viral multiplication><viral pathogen><viral replication><virus infection><virus multiplication><virus pathogen><virus-induced disease>